Risk of Colorectal Cancer and Adenomas in the Families of Patients With Adenomas

Size: px
Start display at page:

Download "Risk of Colorectal Cancer and Adenomas in the Families of Patients With Adenomas"

Transcription

1 Risk of Colorectal Cancer and Adenomas in the Families of Patients With Adenomas A Population-Based Study in Utah Therèse M.F. Tuohy, PhD 1 ; Kerry G. Rowe, MS 2 ; Geraldine P. Mineau, PhD 1,3 ; Richard Pimentel, MS 1 ; Randall W. Burt, MD 1,4 ; and N. Jewel Samadder, MD, MSc 1,4 BACKGROUND: Guidelines recommend that individuals with a first-degree relative (FDR) diagnosed with colorectal cancer (CRC) or advanced adenoma before age 60 years should undergo colonoscopy starting at age 40 years. The authors quantified the risk of adenomas and CRC in FDRs, second-degree relatives (SDRs), and third-degree relatives (TDRs) of patients diagnosed with adenomas and advanced adenomas. METHODS: A population-based, retrospective, case-control study was performed of residents of the state of Utah aged 50 years to 80 years who underwent colonoscopy between 1995 and 2009 at Intermountain Healthcare or the University of Utah. Controls were selected from the population of colonoscopy patients who were free of adenomas or CRC and matched to each case based on sex and birth year. Colonoscopy results were linked with cancer and pedigree information from the Utah Population Database to investigate the familial aggregation of adenomas and CRC using Cox regression analysis. The unit of analysis was the relatives of cases and controls. RESULTS: Of 126,936 patients who underwent colonoscopy, 43,189 had adenomas and 5563 had advanced adenomas and defined the case population. An elevated risk of CRC was found in FDRs (relative risk [RR], 1.35; 95% confidence interval [95% CI], ), SDRs (RR, 1.15; 95% CI, ) of adenoma cases, and in FDRs of advanced adenoma cases (RR, 1.68; 95% CI, ) compared with controls. Approximately 10% of CRCs diagnosed in relatives would have been missed if the current screening guidelines were strictly adhered to. CONCLUSIONS: Relatives of colonoscopy patients with adenomas and advanced adenomas appear to have a significantly elevated risk of developing colorectal neoplasia. These data should be considered when establishing CRC screening guidelines for individuals and their families. Cancer 2014;120: VC 2013 American Cancer Society. KEYWORDS: colorectal cancer, adenomatous polyps, familial, colonoscopy. INTRODUCTION Colorectalcancer(CRC)isthethirdmostcommoncancerin the United States and the second most common cause of cancer-related mortality. 1 The discovery of several high-penetrance susceptibility genes (APC, MLH1, MSH2, MSH6, and PMS2) has lead to a greater awareness of the role of hereditary risk factors for CRC. Familial clustering of CRC is common even when the cases are not part of a defined genetic syndrome. 2 Adenomatous polyps are accepted as the precursor lesion for most cases of CRC. Screening for CRC is widely believed to provide an opportunity to detect patients at risk for developing CRC, remove precursor lesions, or detect patients at an earlier stage of cancer. Adenomas have a higher potential for malignancy both at the time of diagnosis and on follow-up when they measure > 10 mm in diameter and/or present with severe dysplasia and/or a villous component, at which point they are then defined as advanced adenomas (AAs). 3 Screening interventions such as colonoscopy are offered earlier to individuals with such a family history. Specifically, current guidelines recommend that patients with a first-degree relative (FDR) diagnosed with CRC or AA before age 60 years should undergo screening colonoscopy starting at age 40 years or 10 years before the index patient and undergo repeat surveillance every 5 years. 3-6 The current recommendations are primarily based on a prospective study by Fuchs et al that found that FDRs of patients with CRC had a risk of CRC at age 40 years that was similar to the risk of CRC in average-risk patients at the age of 50 years (relative risk [RR], 1.72; 95% confidence interval [95% CI], ). 7 Corresponding author: N. Jewel Samadder, MD, MSc, FRCPC, Hereditary Gastrointestinal Cancer Registry, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112; Fax: (801) ; jewel.samadder@hsc.utah.edu 1 Hereditary Gastrointestinal Cancer Registry, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; 2 Department of Oncology, Intermountain Healthcare, Salt Lake City, Utah; 3 Department of Oncological Sciences, University of Utah, Salt Lake City, Utah; 4 Division of Gastroenterology, Department of Medicine, University of Utah, Salt Lake City, Utah See editorial on pages 4-6, this issue. DOI: /cncr.28227, Received: October 17, 2012; Revised: February 5, 2013; Accepted: February 26, 2013, Published online October 21, 2013 in Wiley Online Library (wileyonlinelibrary.com) Cancer January 1,

2 Because the lifetime risk of CRC is approximately 6%, millions of Americans will be counseled to undergo colonoscopy at age 40 years, based on a positive family history of CRC or AA. Therefore, it is important to validate the elevated risk of CRC in the relatives of patients with adenomas or AAs in a population-based study, and to examine that risk in immediate and more distant relatives, as well as by age groups. In this retrospective, population-based, case-control study, we quantified the risk of CRC and adenomas in the FDRs, second-degree relatives (SDRs), or third-degree relatives (TDRs; first cousins) of individuals with an adenoma or advanced adenoma, stratified by age at diagnosis. To the best of our knowledge, the current study is the first population-based assessment of the risk of colorectal neoplasia in distant relatives of individuals with an adenomatous polyp and also examines this risk based on the age of the patient at the time of the adenoma diagnosis. Comprehensive family histories were available through extensive Utah genealogies linked to a statewide cancer registry and medical records that do not rely on self-report. The design of the current study is feasible because of these unique linked resources. MATERIALS AND METHODS Design This study was approved by the Institutional Review Boards of the University of Utah and Intermountain Healthcare (IHC) and by the Utah Resource for Genetic and Epidemiologic Research ( rge/), an administrative oversight board charged by the University of Utah to govern access to the Utah Population Database (UPDB). We performed a population-based, retrospective, case-control study of residents in the state of Utah aged 50 years to 80 years who underwent colonoscopy from February 15, 1995 to January 31, 2009 at IHC and the University of Utah Health Sciences (UUHSC) clinical facilities. Deidentified medical information regarding patients undergoing colonoscopy at IHC and UUHSC was merged with family structure in the UPDB genealogies, which include cancer histories from the Utah Cancer Registry (UCR), a Surveillance, Epidemiology, and End Results (SEER) registry, to investigate the familial aggregation of CRC and colon adenomas. Description of Databases The current investigation takes advantage of unique Utah databases. The study required patient-level data integration between IHC, the UUHSC, and the UPDB. The UPDB combines genealogies often dating back to the early 1800s with data from statewide resources, including the UCR, statewide inpatient discharge and ambulatory surgery records, and driver license data, as well as birth and death certificates. This resource also has been linked to the demographic records from the UUHSC 8 and IHC. 9 In combination, the UUHSC and IHC together provide cancer-related care to > 80% of the Utah population. Previous demographic and genetic analyses have shown that the population recorded in the UPDB is genetically representative of US white and northern European populations, with a low level of inbreeding. 10 Of particular interest for the current study is the inclusion of the UCR records as part of the UPDB. The UCR is a statewide cancer registry that was established in 1966, and since 1973 it has been part of the SEER network of the National Cancer Institute registries. Given an ongoing and accurate assessment of a family history of cancer that does not depend on self-report, the UPDB provides a valuable resource for a thorough analysis of the familial nature of colorectal neoplasia. Linkage of Electronic Medical Record Data to the UPDB These linked resources have been used to assess colonoscopy screening rates in high-risk individuals 11 as well as recent studies on preeclampsia, 12 spontaneous preterm delivery, 13 cancer in twins, 14 heritability of inflammatory bowel disease, 15 and effects of family conditions on laterlife mortality. 16 Study Definition Colonoscopy was extracted from the institutional records using Current Procedural Terminology codes 45378, 45391, or Case subjects were defined as having adenomas detected during their colonoscopy as outlined in Figure 1. Adenomas were identified through pathology reports. For the purposes of the current study, AAs were defined as those that had any component of villous histology, also identified through pathology reports. We could not identify the other criteria associated with a definition of AA (measuring > 10 mm or high-grade dysplasia). The analysis evaluated the RR of CRC and colorectal neoplasia diagnosed in the FDRs, SDRs, and TDRs of cases compared with relatives of controls. Control Selection For each case patient, 1 randomly selected, age- and sexmatched control was used. These controls were sampled without replacement and were selected from the population of colonoscopy patients who did not have 36 Cancer January 1, 2014

3 Familial Risk of Colorectal Neoplasia/Tuohy et al Figure 1. Study flow diagram is shown. IHC indicates Intermountain Healthcare; UUHSC, University of Utah Health Sciences; CRC, colorectal cancer; UPDB, Utah Population Database; FDR, first-degree relative (parent, child, sibling); SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). adenomatous polyps removed at the time of any colonoscopy performed between 1995 and 2009, but they could have had other findings. Controls had to have follow-up in the UPDB that was at least as long as their respective matched case. Follow-up was based on the most recent date an individual had an event recorded in Utah from vital records (deaths, births, adoptions, marriages, and divorces; Utah driver s license registrations and renewals; voter registrations; and statewide inpatient and ambulatory surgeries). Records are linked at least annually. Statistical Analysis Using software developed specifically for UPDB kinship analysis, 17 the magnitude of familial risk was estimated by Cox regression analysis to assess the RR of CRC and adenoma for FDRs, SDRs, and TDRs of colonoscopy patients who themselves were diagnosed with adenomas. 18 Because observations within families are nonindependent, a robust variance estimator for clustered data similar to the generalized estimating equation approach was incorporated. 19 This analysis corrects for the issue of families being analyzed multiple times because of multiple cases of CRC. The percentage of FDRs diagnosed with CRC based on age groups was also computed. RESULTS The current study analyzed the RRs of colorectal neoplasia from 27,646 colonoscopy patients at UUHSC and 103,680 colonoscopy patients from IHC. When combined and accounting for patients who had procedures performed in both hospital systems, there were 126,936 unique individuals who had received a colonoscopy. A total of 43,189 patients had an adenomatous polyp removed at their index or first colonoscopy and defined the case population. For cases of AA, we used 5563 Cancer January 1,

4 patients who had an adenoma with villous features removed at the index or first colonoscopy. Table 1 shows the descriptive features of cases (colonoscopy patients with a finding of an adenomatous polyp) and controls in the current study. The mean age at the time the procedure was performed for both cases and controls was similar at 61 years and 60 years, respectively. For cases and controls, the mean number of relatives with colonoscopies was similar, thereby reducing the likelihood of detection bias. Colonoscopy use among FDRs was approximately 30%, which is similar to statewide use of CRC screening in Utah. Tables 2 and 3 show the distribution of CRC among relatives of cases with adenoma and AA and controls based on the degree of relation. An elevated risk of CRC was found in FDRs of cases with adenomas (RR, 1.35; 95% CI, ) and advanced adenomas (RR, 1.68; 95% CI, ) compared with relatives of controls. TABLE 1. Descriptive Characteristics of Colonoscopy Patients With Adenomas (Cases) and Matched Controls Cases a Controls b Characteristic Sex Male Female Male Female No. 24,969 18,220 23,138 18,003 % Mean age at procedure, y Mean no. of FDRs with colonoscopy Mean no. of SDRs with colonoscopy Mean no. of TDRs with colonoscopy Abbreviations: FDR, first-degree relative (parent, child, sibling); SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). a Cases diagnosed with adenomas at time of colonoscopy between 1995 and b Controls selected from colonoscopy cohort, without findings of adenomas or colorectal cancer. Matched by sex and birth year and had follow-up at least as long as the date of the case diagnosis. Although the SDRs of cases who had an adenoma removed had an elevated risk of CRC (RR, 1.15; 95% CI, ), the SDRs of cases with AAs did not. The TDRs of cases with adenomas were found to have a slightly elevated risk of CRC (RR, 1.06; 95% CI, ). Using the adenoma and advanced adenoma cases and controls cited above, we also examined their relatives risk of developing similar polyps (Tables 4 and 5). The RR of an adenoma detected in a FDR of a patient affected by a similar polyp was 1.33 (95% CI, ). This association demonstrated a familial trend, dependent on the degree of relationship, and decreasing as the level of the relationship became more distant. The RRs for an adenoma in a SDR was 1.15 (95% CI, ), and was 1.09 (95% CI, ) in a TDR. Similarly, the RR of an advanced adenoma in a FDR affected by a similar advanced polyp was 1.65 (95% CI, ), and was 1.06 (95% CI, ) in an SDR and 1.96 (95% CI, ) in a TDR. When stratified by age at the time of the diagnosis of colorectal neoplasia in cases, the FDRs and SDRs of those diagnosed with an adenoma at age < 60 years had a greater risk of CRC compared with relatives of controls (RR, 1.41; 95% CI, ). However, even for cases diagnosed with an adenoma at age 60 years, FDRs had a moderately elevated risk of CRC (RR, 1.23; 95% CI, ) (Table 6). A similar elevated risk of CRC was observed in the FDRs of cases with advanced adenoma regardless of their age at the time of polyp diagnosis (Table 7). Tables 8 and 9 show the breakdown by age group of FDRs of cases diagnosed with adenoma and advanced adenoma stratified by age and demonstrate that 10% of CRCs would have been missed using the current guidelines, which do not advise screening at a younger age for FDRs of individuals diagnosed with an adenoma at age < 60 years. TABLE 2. Relative Risk of CRC in Relatives of Cases With Adenomas CRC in Relatives of Probands Diagnosed With Adenomas Cases Controls Relationship Affected Unaffected Affected Unaffected RR 95% CI P FDR , ,962, <.001 SDR , , <.001 TDR a , , Abbreviations: 95% CI, 95% confidence interval; CRC, colorectal cancer; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, seconddegree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). 38 Cancer January 1, 2014

5 Familial Risk of Colorectal Neoplasia/Tuohy et al TABLE 3. Relative Risk of CRC in Relatives of Cases With Advanced Adenomas CRC in Relatives of Probands Diagnosed With AAs Cases Controls Relationship Affected Unaffected Affected Unaffected RR 95% CI P FDR , , <.001 SDR 83 39, , TDR a , , Abbreviations: 95% CI, 95% confidence interval; AA, advanced adenoma; CRC, colorectal cancer; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). TABLE 4. Relative Risk of Adenomas in Relatives of Cases With Adenomas Adenomas in Relatives of Probands Diagnosed With Adenomas Cases Controls Relationship Affected Unaffected Affected Unaffected RR 95% CI P FDR <.001 SDR <.001 TDR a 12,740 20,827 12,402 22, <.001 Abbreviations: 95% CI, 95% confidence interval; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). TABLE 5. Relative Risk of Advanced Adenomas in Relatives of Cases With Advanced Villous Adenomas AAs in Relatives of Probands Diagnosed With AAs Cases Controls Relationship Affected Unaffected Affected Unaffected RR 95% CI P FDR <.001 SDR TDR a Abbreviations: 95% CI, 95% confidence interval; AA, advanced adenoma; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, seconddegree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). DISCUSSION In the current study, we report that FDRs, SDRs, and TDRs of patients with adenomas and advanced adenomas have an increased risk of developing adenomas or CRC themselves. Whereas FDRs of patients with adenomas were found to have only a moderately increased risk of colorectal neoplasia of 35%, the FDRs of patients with advanced adenomas had a nearly 70% elevated risk of developing colorectal neoplasia. This supports current guidelines for increased CRC surveillance in the relatives of patients with advanced adenomas. Although this observation in FDRs could be related in part to a shared environment, this is unlikely to be true for SDRs and TDRs. The results of the current study add substantially to the available literature in view of its number of inherent strengths. First, it defines precise risk levels for both CRC and adenomatous polyps not only in FDRs but also in the SDRs and TDRs of patients with adenoma and AAs. Second, it is population-based, which avoids many of the recruitment biases inherent to referral-based and registrybased studies. Third, patient recall biases, which occur frequently in many family studies, are avoided by using primary medical records that are linked to cancer registry and genealogical records. Fourth, cases are defined as those who have undergone a colonoscopy, which reflects those patients seen by gastroenterologists in clinical practice. Finally, the numbers of cases and controls are Cancer January 1,

6 TABLE 6. Relative Risk of CRC in Relatives of Cases With Adenomas, Stratified by Age at Diagnosis Adenoma Cases Aged <60 Years Adenoma Cases Aged 60 Years Relationship RR 95% CI P RR 95% CI P FDR < SDR TDR a Abbreviations: 95% CI, 95% confidence interval; CRC, colorectal cancer; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, great-grandparent). TABLE 7. Relative Risk of CRC in Relatives of Cases With Advanced Adenomas, Stratified by Age at Diagnosis AA Cases Aged <60 Years AA Cases Aged 60 Years Relationship RR 95% CI P RR 95% CI P FDR SDR TDR a Abbreviations: 95% CI, 95% confidence interval; AA, advanced adenoma; CRC, colorectal cancer; FDR, first-degree relative (parent, child, sibling); RR, relative risk; SDR, second-degree relative (aunt/uncle, niece/nephew, grandparent/grandchild); TDR, third-degree relative (first cousin, greatgrandparent). TABLE 8. Percentage of FDRs Diagnosed With CRC Based on Age Groups, Stratified by Age of Case With Adenoma Adenoma Case Adenoma Case Age Group, Age <60 Years Aged 60 Years Relationship Years No. (%) No. (%) FDR with CRC <40 24 (2.8) 0 40 to <50 63 (7.2) (90.0) 430 (100) Abbreviations: CRC, colorectal cancer; FDR, first-degree relative (parent, child, sibling). sufficiently large to make precise cancer and adenoma risk estimates in various relatives by age group. Two case-control design studies from France found an elevated risk of developing adenomas or CRC in the FDRs of patients with large adenomas. 20,21 This was also supported by a smaller US study that demonstrated only a modest and nonsignificant increase in the risk of CRC in the relatives of patients with small tubular adenomas (odds ratio [OR], 1.26; 95% CI, ) TABLE 9. Percentage of FDRs Diagnosed With CRC Based on Age Groups, Stratified by Age of Case With Advanced Adenoma AA Case Aged AA Case Aged Age Group, <60 Years 60 Years Relationship Years No. (%) No. (%) FDR with CRC <40 1 (1.4) 0 40 to <50 4 (5.8) (92.8) 68 (100) Abbreviations: AA, advanced adenoma; CRC, colorectal cancer; FDR, firstdegree relative (parent, child, sibling). and a significant increase in the relatives of patients with AAs (those measuring > 10 mm in size and/or with a villous component or high-grade dysplasia), with an OR of 1.62 (95% CI, ). 22 This is similar to the current study findings of a moderate 35% increased risk of CRC in the FDRs of patients with adenoma (OR, 1.35; 95% CI, ) and a nearly 70% elevated risk of CRC in the FDRs of patients with villous adenomas (OR, 1.68; 95% CI, ). Similarly, in a 2001 systematic review, 8 of 9 studies found an increased risk of CRC associated with adenomas in a FDR, with a pooled OR of 1.99 (95% CI, ). 23 Despite variations in the study designs and populations examined, these studies support the findings of the current study that FDRs of patients with adenomas have a moderately increased risk of developing colorectal neoplasia whereas relatives of those with AAs (villous histology or large size) are at a higher risk of developing colorectal neoplasia. The results of the current study add considerable support to these other studies by examining risk in a population data set, but also extend the findings robustly to older relatives and more distant relatives. The most recent of these systematic reviews of familial CRC studies concluded that studies published to date have had several design problems that affect their validity and generalizability. 24 Of 12 identified studies, 10 did not answer the primary question of whether having a FDR with an adenoma increased a patient s risk of developing CRC. The remaining 2 studies suffered from a lack of generalizability due to racial homogeneity and a lack of validation of family history and colonoscopy records. The authors advocated for a cohort or cross-sectional design study that could identify all relatives and have access to medical records to establish a diagnosis of CRC, thereby reducing the effect of patient recall bias. 24 The design and data sets of the current study mitigate some of the weakness identified in this systematic 40 Cancer January 1, 2014

7 Familial Risk of Colorectal Neoplasia/Tuohy et al review. To the best of our knowledge, the current study is the largest to date of familial colorectal neoplasia, thus giving it power to examine risk in SDRs and TDRs as well as FDRs. Recall bias, as mentioned above, is avoided by having primary clinical records as well as validated genealogical records for familial relationships. Detection bias, in which relatives of cases may be more likely to undergo colonoscopy and have adenomas found than controls, is also a common issue. Although detection bias may be present in the current study, we were able to demonstrate that a similar number of relatives of cases and controls had undergone colonoscopy examinations. The current study is population-based, reflecting standard-of-care clinical practice in both a large academic medical center and a managed care organization that together provide care to approximately 85% of the population of the state of Utah. This size and inclusiveness also reduces referral bias. The population of Utah is also representative of US/European white populations, with a low level of inbreeding. Therefore, the results are applicable to similar populations in the United States. 10 To the best of our knowledge, only a few studies to date have examined the risk of CRC in relatives of patients with adenoma stratified by the age of the index case. The results of the current study are similar to the findings of studies from France 20 and New York State, 25,26 in which the risk of CRC among family members was found to increase with decreasing age at the time of diagnosis of adenoma in the index case. Familial risk for older-age probands is an important point, because increased familial risk when the index case (proband) is aged > 60 years is often not appreciated. In the current study, we were also able to examine patient age when CRC occurred in FDRs, both when index cases were age < 60 years and 60 years at the time of diagnosis of adenoma or advanced adenoma (Table 6). With this analysis, we found approximately 10% and 1.5%, respectively, of FDRs of cases of adenoma and villous adenoma developed CRC at ages younger than those currently recommended 4 to start colonoscopy screening (based on familial risk), and therefore would have been missed. There are certain limitations of the current study that also deserve mention. Patients with known hereditary cancer syndromes, in particular familial adenomatous polyposis and Lynch syndrome, could not specifically be excluded. However, because both of these conditions are rare, and account for less than approximately 3% of all colon cancers, they are unlikely to modify the statistical associations demonstrated herein. Another issue is that the extraction of data from electronic medical records has limitations with regard to the information that can be gathered. The indication for colonoscopy was not specifically ascertained and therefore might introduce bias. Many screening procedures are also coded for a diagnosis found at colonoscopy or other unrelated symptoms and thus it would be nearly impossible to establish a study population of only screening colonoscopies. However, the ascertainment of the current study reflects gastroenterologists usual clinical practice of colonoscopy, with patients referred for screening as well as other indications. We also did not have information available regarding the documented completeness of the colonoscopic examination or the quality of the bowel preparation, although these issues are likely to be similarly reflected in both the case and control groups. We conducted a retrospective, population-based, case-control study in Utah, demonstrating that FDRs, SDRs, and TDRs of patients with adenomas and AAs who are undergoing colonoscopy are at an elevated risk of developing colorectal neoplasia (CRC, adenomas, and AAs). An increased risk was observed in relatives regardless of the age of the index patient at the time of adenoma diagnosis, although the risk was greater for index cases at a younger age. The results of the current study confirm and expand the evidence for a common familial risk for colorectal neoplasia and should become part of the data considered when screening strategies are synthesized. The data from the current study support the current screening guidelines for individuals with a family history of advanced adenomas and raise the issue of whether more aggressive screening should be considered for the FDRs of patients with adenomas diagnosed at age 60 years. Future studies to examine the risk of CRC in the relatives of patients diagnosed with AAs based on other components of the definition (large size or high-grade dysplasia) are required to validate the current CRC screening guidelines. The results of the current study further support inherited factors as a part of the etiology of colorectal neoplasia. Clinician awareness of the familial risks demonstrated in the current study will be of considerable assistance when working with individuals and families with colorectal neoplasia. FUNDING SUPPORT Supported by National Cancer Institute grants P01-CA073992and R01-CA (both to Dr. Burt). Partial support for the Utah Population Database is provided by the Huntsman Cancer Institute (HCI) and the HCI Cancer Center support grant P30CA042014, from the National Cancer Institute. The Utah Cancer Registry is Cancer January 1,

8 funded by contract HHSN C from the National Cancer Institute s Surveillance, Epidemiology, and End Results (SEER) program, with additional support from the Utah State Department of Health and the University of Utah. CONFLICT OF INTEREST DISCLOSURES Dr. Burt is a consultant for and has received payment for lectures including as a member of the Speakers Bureau from Myriad Genetics. Dr. Samadder has received speaking fees from Cook Medical Inc. REFERENCES 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin. 2009;59: Burt RW, DiSario JA, Cannon-Albright L. Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med. 1995;46: Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130: Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104: Burt RW, Barthel JS, Dunn KB, et al; NCCN. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010;8: Levin B, Lieberman DA, McFarland B, et al; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134: Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331: DuVall SL, Kerber RA, Thomas A. Extending the Fellegi-Sunter probabilistic record linkage method for approximate field comparators. J Biomed Inform. 2010;43: DuVall SL, Fraser AM, Rowe K, Thomas A, Mineau GP.et al. Evaluation of record linkage between a large healthcare provider and the Utah Population Database. J Am Med Inform Assoc. 2012;19:e54- e Jorde LB. Inbreeding in the Utah Mormons: an evaluation of estimates based on pedigrees, isonymy, and migration matrices. Ann Hum Genet. 1989;53: Taylor DP, Cannon-Albright LA, Sweeney C, et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med. 2011;13: Aagaard-Tillery KM, Stoddard GJ, Holmgren C, et al. Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol. 2006; 195: Esplin MS, O Brien E, Fraser A, et al. Estimating recurrence of spontaneous preterm delivery. Obstet Gynecol. 2008;112: Neale RE, Mineau G, Whiteman DC, et al. Childhood and adult cancer in twins: evidence from the Utah genealogy. Cancer Epidemiol Biomarkers Prev. 2005;14: Guthery SL, Mineau G, Pimentel R, et al. Inflammatory bowel disease aggregation in Utah kindreds. Inflamm Bowel Dis. 2011;17: Smith KR, Mineau GP, Garibotti G, Kerber R. Effects of childhood and middle-adulthood family conditions on later-life mortality: evidence from the Utah Population Database, Soc Sci Med. 2009;68: Kerber RA, O Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer. 2005;103: Kerber RA. Method for calculating risk associated with family history of a disease. Genet Epidemiol. 1995;12: Williams RL. A note on robust variance estimation for clustercorrelated data. Biometrics. 2000;56: Cottet V, Pariente A, Nalet B, et al. Colonoscopic screening of firstdegree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology. 2007;133: Pariente A, Milan C, Lafon J, Faivre J. Colonoscopic screening in first-degree relatives of patients with sporadicç colorectal cancer: a case-control study. The Association Nationale des Gastroenterologues des Hopitaux and Registre Bourguignon des Cancers Digestifs (INSERM CRI 9505). Gastroenterology. 1998;115: Lynch KL, Ahnen DJ, Byers T, et al. First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clin Gastroenterol Hepatol. 2003;1: Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96: Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. Ann Intern Med. 2012;156: Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med. 1998;128: Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med. 1996;334: Cancer January 1, 2014

How to Screen a patient with a Family History of Adenoma(s)

How to Screen a patient with a Family History of Adenoma(s) How to Screen a patient with a Family History of Adenoma(s) CDDW Banff 3-5-17 David Lieberman MD Chief, Division of Gastroenterology and Hepatology Oregon Health and Science University Disclosures 2016

More information

Of the projected nearly 150,000 new cases of large-bowel. A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk

Of the projected nearly 150,000 new cases of large-bowel. A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1080 1084 A Familial Component to Human Rectal Cancer, Independent of Colon Cancer Risk JOHN SCOTT MAUL,* RANDALL W. BURT, and LISA A. CANNON ALBRIGHT *Department

More information

Accepted Manuscript. Utility of Genetic Testing in Persons with Multiple Colorectal Polyps. Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS

Accepted Manuscript. Utility of Genetic Testing in Persons with Multiple Colorectal Polyps. Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS Accepted Manuscript Utility of Genetic Testing in Persons with Multiple Colorectal Polyps Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS PII: S1542-3565(19)30259-9 DOI: https://doi.org/10.1016/j.cgh.2019.03.007

More information

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,

More information

Colonic Adenoma Risk in Familial Colorectal Cancer A Study of Six Extended Kindreds

Colonic Adenoma Risk in Familial Colorectal Cancer A Study of Six Extended Kindreds American Journal of Gastroenterology ISSN 0002-9270 C 2008 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2008.02019.x Published by Blackwell Publishing ORIGINAL CONTRIBUTIONS Colon/Small Bowel

More information

Heather Hampel, MS, CGC Professor, Division of Human Genetics

Heather Hampel, MS, CGC Professor, Division of Human Genetics Familial, Hereditary, and Early Age Onset Colorectal Cancer: A Module Designed to Assist Primary Care Clinician s in the Identification of Individuals at Increased Risk and Facilitate Earliest Possible

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions

More information

The Impact of Family History of Colon Cancer on Survival after Diagnosis with Colon Cancer

The Impact of Family History of Colon Cancer on Survival after Diagnosis with Colon Cancer International Journal of Epidemiology O International Epfdemlotoglcal Association 1995 Vol. 24, No. 5 Printed In Great Britain The Impact of Family History of Colon Cancer on Survival after Diagnosis with

More information

C olorectal adenomas are reputed to be precancerous

C olorectal adenomas are reputed to be precancerous 568 COLORECTAL CANCER Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese Y Yamaji, T Mitsushima, H Ikuma, H Watabe, M Okamoto, T

More information

Colorectal cancer is one of the most common cancers

Colorectal cancer is one of the most common cancers GASTROENTEROLOGY 2007;133:1086 1092 Colonoscopic Screening of First-Degree Relatives of Patients With Large Adenomas: Increased Risk of Colorectal Tumors VANESSA COTTET,*, ALEXANDRE PARIENTE, BERNARD NALET,

More information

Colorectal Cancer Screening and Surveillance

Colorectal Cancer Screening and Surveillance 1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal

More information

Five-Year Risk of Colorectal Neoplasia after Negative Screening Colonoscopy

Five-Year Risk of Colorectal Neoplasia after Negative Screening Colonoscopy The new england journal of medicine original article Five-Year Risk of Colorectal Neoplasia after Negative Screening Colonoscopy Thomas F. Imperiale, M.D., Elizabeth A. Glowinski, R.N., Ching Lin-Cooper,

More information

Colonoscopy with polypectomy significantly reduces colorectal

Colonoscopy with polypectomy significantly reduces colorectal CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:562 567 Utilization and Yield of Surveillance Colonoscopy in the Continued Follow-Up Study of the Polyp Prevention Trial ADEYINKA O. LAIYEMO,*, PAUL F. PINSKY,

More information

Title Description Type / Priority

Title Description Type / Priority Merit-based Incentive Payment system (MIPS) 2019 Qualified Clinical Data Registry (QCDR) Measure Specifications Summary Listing of QCDR measures supported by the NHCR Measure # NHCR4 NHCR5 GIQIC12 GIQIC15

More information

Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.

Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D. Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,

More information

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics

More information

Merit-based Incentive Payment system (MIPS) 2018 Qualified Clinical Data Registry (QCDR) Measure Specifications

Merit-based Incentive Payment system (MIPS) 2018 Qualified Clinical Data Registry (QCDR) Measure Specifications Merit-based Incentive Payment system (MIPS) 2018 Qualified Clinical Data Registry (QCDR) Measure Specifications This document contains a listing of the clinical quality measures which the New Hampshire

More information

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace

More information

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation

More information

Precision Cancer Prevention: Hereditary Polyposis Syndromes

Precision Cancer Prevention: Hereditary Polyposis Syndromes Precision Cancer Prevention: Hereditary Polyposis Syndromes N. Jewel Samadder, MD, MSC, FRCPC HUNTSMAN CANCER INSTITUTE UNIVERSITY OF UTAH Familial Adenomatous Polyposis Familial Adenomatous Polyposis

More information

Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right?

Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Quality of and compliance with colonoscopy in Lynch Syndrome surveillance: are we getting it right? Hartery K 1, Sukha A 1, Thomas-Gibson S 1, Thomas H 1,2, Latchford A 1,2. 1 Wolfson Endoscopy Unit, St.

More information

PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)

PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II) Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline

More information

Increased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma

Increased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma Research Original Investigation Increased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma Gretchen M. Oakley, MD; Karen Curtin, PhD; Lester Layfield, MD; Elke Jarboe, MD; Luke O. Buchmann,

More information

MSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table

MSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk

More information

Research Article Adenoma and Polyp Detection Rates in Colonoscopy according to Indication

Research Article Adenoma and Polyp Detection Rates in Colonoscopy according to Indication Hindawi Gastroenterology Research and Practice Volume 2017, Article ID 7207595, 6 pages https://doi.org/10.1155/2017/7207595 Research Article Adenoma and Polyp Detection Rates in Colonoscopy according

More information

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial

The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an

More information

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer

Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer Douglas K. Rex, MD, MACG 1, C. Richard Boland, MD 2, Jason A. Dominitz,

More information

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries

IEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries for Medicare Beneficiaries Policy: Based on our review of the available evidence, the IEHP UM Subcommittee adopts the use of Cologuard TM - a multi-target stool DNA test as a colorectal cancer screening

More information

Increasing the number of older persons in the United

Increasing the number of older persons in the United Current Capacity for Endoscopic Colorectal Cancer Screening in the United States: Data from the National Cancer Institute Survey of Colorectal Cancer Screening Practices Martin L. Brown, PhD, Carrie N.

More information

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013 For identification, support and follow up related to Familial Gastrointestinal Cancer conditions South Island Cancer Nurses Network September 2013 Who are we? Specialist multidisciplinary team: Nurse coordinators,

More information

Cascade Genetic Testing in Families with Lynch Syndrome. Elena M. Stoffel MD MPH University of Michigan January 26, 2016

Cascade Genetic Testing in Families with Lynch Syndrome. Elena M. Stoffel MD MPH University of Michigan January 26, 2016 Cascade Genetic Testing in Families with Lynch Syndrome Elena M. Stoffel MD MPH University of Michigan January 26, 2016 Cascade Genetic Screening An active process to find relatives of patients affected

More information

Familial Risk and Colorectal Cancer Screening. December 8th, :00pm ET

Familial Risk and Colorectal Cancer Screening. December 8th, :00pm ET Familial Risk and Colorectal Cancer Screening December 8th, 2016 1:00pm ET Purpose of Today s Webinar Understand what we know and don t know about CRC screening for those with a familial risk of CRC Review

More information

GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department

GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY

More information

MLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table

MLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table MLH1 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Cancer (HNPCC) MLH1 Summary Cancer Risk Table CANCER GENETIC CANCER RISK Endometrial Other MLH1 gene Overview Lynch syndrome 1,

More information

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor

More information

Incidence and Multiplicities of Adenomatous Polyps in TNM Stage I Colorectal Cancer in Korea

Incidence and Multiplicities of Adenomatous Polyps in TNM Stage I Colorectal Cancer in Korea Original Article Journal of the Korean Society of J Korean Soc Coloproctol 2012;28(4):213-218 http://dx.doi.org/10.3393/jksc.2012.28.4.213 pissn 2093-7822 eissn 2093-7830 Incidence and Multiplicities of

More information

YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)

YES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,

More information

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2 Supplementary Table 1. Study Characteristics Author, yr Design Winawer et al., 6 1993 National Polyp Study Jorgensen et al., 9 1995 Funen Adenoma Follow-up Study USA Multi-center, RCT for timing of surveillance

More information

How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE

How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov R. Sáenz, FACG,FASGE How to start a screening Program? WEO Colorectal Cancer Screening Committee Meeting Brasilia Nov 11 2017 R. Sáenz, FACG,FASGE Wheel has been discovered already Policy Planning Thanks to GBD Big Data CRC

More information

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer

Clinical Policy: DNA Analysis of Stool to Screen for Colorectal Cancer Clinical Policy: to Screen for Colorectal Cancer Reference Number: CP.MP.125 Last Review Date: 07/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding

More information

Supporting people at higher risk of bowel cancer

Supporting people at higher risk of bowel cancer #never2young Never too young: Supporting people at higher risk of bowel cancer Campaign briefing Supporting people at higher risk of bowel cancer Bowel cancer is the second most common cause of cancer

More information

Digestive Health Southwest Endoscopy 2016 Quality Report

Digestive Health Southwest Endoscopy 2016 Quality Report Digestive Health 2016 Quality Report Our 2016 our quality and value management program focused on one primary area of interest: Performing high quality colonoscopy High quality Colonoscopy We selected

More information

PMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table

PMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk

More information

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis Screening for Colorectal Neoplasia in Inflammatory Bowel Disease Francis A. Farraye MD, MSc Clinical Director, Section of Gastroenterology Co-Director, Center for Digestive Disorders Boston Medical Center

More information

Historical. Note: The parenthetical numbers in the Clinical Indications section refer to the source documents cited in the References Section below.

Historical. Note: The parenthetical numbers in the Clinical Indications section refer to the source documents cited in the References Section below. Clinical UM Guideline Subject: Colonoscopy Guideline #: CG-SURG-01 Current Effective Date: 01/21/2015 Status: Revised Last Review Date: 05/15/2014 Description Colonoscopy describes the direct visual inspection

More information

Colonoscopy MM /01/2010. PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient

Colonoscopy MM /01/2010. PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient Colonoscopy Policy Number: Original Effective Date: MM.12.003 12/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration 10/01/2017 Section: Surgery Place(s) of Service: Outpatient

More information

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,

More information

SURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases

SURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases SURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases Carol Sweeney PhD Director, Utah Cancer Registry Supported by CDC UNIVERSITY OF UTAH HEALTH,

More information

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE The Condition 1. The condition should be an important health problem Colorectal

More information

Accepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A.

Accepted Manuscript. En bloc resection for mm polyps to reduce post-colonoscopy cancer and surveillance. C. Hassan, M. Rutter, A. Accepted Manuscript En bloc resection for 10-20 mm polyps to reduce post-colonoscopy cancer and surveillance C. Hassan, M. Rutter, A. Repici PII: S1542-3565(19)30412-4 DOI: https://doi.org/10.1016/j.cgh.2019.04.022

More information

Cologuard Screening for Colorectal Cancer

Cologuard Screening for Colorectal Cancer Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: colonoscopic surveillance for prevention of colorectal cancer in patients with ulcerative colitis, Crohn

More information

Screening for Colorectal Cancer in the Elderly. The Broad Perspective

Screening for Colorectal Cancer in the Elderly. The Broad Perspective Screening for Colorectal Cancer in the Elderly Charles J. Kahi, MD, MSCR Indiana University School of Medicine Richard L. Roudebush VA Medical Center Indianapolis, Indiana ACG Regional Midwest Course Symposium

More information

R. J. L. F. Loffeld, 1 P. E. P. Dekkers, 2 and M. Flens Introduction

R. J. L. F. Loffeld, 1 P. E. P. Dekkers, 2 and M. Flens Introduction ISRN Gastroenterology Volume 213, Article ID 87138, 5 pages http://dx.doi.org/1.1155/213/87138 Research Article The Incidence of Colorectal Cancer Is Decreasing in the Older Age Cohorts in the Zaanstreek

More information

The Prevalence Rate and Anatomic Location of Colorectal Adenoma and Cancer Detected by Colonoscopy in Average-Risk Individuals Aged Years

The Prevalence Rate and Anatomic Location of Colorectal Adenoma and Cancer Detected by Colonoscopy in Average-Risk Individuals Aged Years American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00430.x Published by Blackwell Publishing The Prevalence Rate and Anatomic Location

More information

2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)

2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests) Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,

More information

GIQIC18 Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm

GIQIC18 Appropriate follow-up interval of not less than 5 years for colonoscopies with findings of 1-2 tubular adenomas < 10 mm GI Quality Improvement Consortium, Ltd. (GIQuIC) 1 Following is an overview of the clinical quality measures in GIQuIC that can be reported to CMS for the Quality performance category of the Merit-Based

More information

Colorectal Cancer Screening

Colorectal Cancer Screening Recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer Colorectal Cancer Screening Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Levin TR, Lieberman D, Robertson

More information

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy

More information

Screening & Surveillance Guidelines

Screening & Surveillance Guidelines Chapter 2 Screening & Surveillance Guidelines I. Eligibility Coloradans ages 50 and older (average risk) or under 50 at elevated risk for colon cancer (personal or family history) that meet the following

More information

Analysis of current testing practices

Analysis of current testing practices Clin Genet 2015: 87: 368 372 Printed in Singapore. All rights reserved Short Report Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis 2014 John Wiley & Sons

More information

Hamideh Salimzadeh, PhD Assistant Professor, Digestive Diseases Research Center,Tehran University of Medical Sciences, Shariati Hospital, North

Hamideh Salimzadeh, PhD Assistant Professor, Digestive Diseases Research Center,Tehran University of Medical Sciences, Shariati Hospital, North Hamideh Salimzadeh, PhD Assistant Professor, Digestive Diseases Research Center,Tehran University of Medical Sciences, Shariati Hospital, North Kargar Avenue 14666 Tehran, Iran. Tel: +98-21-82415415 Fax:

More information

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,

More information

FORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas

FORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas FORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas CRC Screening is Increasing Up to date with recommended screening in U.S.: 54% in 2002 65% in 2010 80% goal for 2018 More people are getting

More information

Sequential screening in the early diagnosis of colorectal cancer in the community

Sequential screening in the early diagnosis of colorectal cancer in the community Journal of Public Health: From Theory to Practice https://doi.org/10.1007/s10389-019-01024-0 ORIGINAL ARTICLE Sequential screening in the early diagnosis of colorectal cancer in the community Ming-sheng

More information

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) A Patient s Guide to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary

More information

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care

Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:

More information

Clinical UM Guideline

Clinical UM Guideline Subject: Guideline #: Current Effective Date: 06/28/2016 Status: Revised Last Review Date: 05/05/2016 Description This document addresses colonoscopy, an endoscopic procedure which allows direct visual

More information

Early detection and screening for colorectal neoplasia

Early detection and screening for colorectal neoplasia Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.

More information

ACG Clinical Guideline: Colorectal Cancer Screening

ACG Clinical Guideline: Colorectal Cancer Screening ACG Clinical Guideline: Colorectal Cancer Screening Douglas K. Rex, MD, FACG 1, David A. Johnson, MD, FACG 2, Joseph C. Anderson, MD 3, Phillip S. Schoenfeld, MD, MSEd, MSc (Epi), FACG 4, Carol A. Burke,

More information

Cancer Screenings and Early Diagnostics

Cancer Screenings and Early Diagnostics Cancer Screenings and Early Diagnostics Ankur R. Parikh, D.O. Medical Director, Center for Advanced Individual Medicine Hematologist/Medical Oncologist Atlantic Regional Osteopathic Convention April 6

More information

Summary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4):

Summary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4): Rep Pract Oncol Radiother, 2007; 12(4): 201-206 Original Paper Received: 2006.12.19 Accepted: 2007.04.02 Published: 2007.08.31 Authors Contribution: A Study Design B Data Collection C Statistical Analysis

More information

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer? Important points The most important factors that can influence an individual s chance of developing bowel cancer are getting older and having a family history of bowel cancer A family history of bowel

More information

Policy Specific Section: March 1, 2005 January 30, 2015

Policy Specific Section: March 1, 2005 January 30, 2015 Medical Policy Fecal DNA Analysis for Colorectal Cancer Screening Type: Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: March 1, 2005

More information

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care

Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care Measure #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clincal Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage

More information

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening. Summary

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening. Summary Page: 1 of 11 Last Review Status/Date: March 2015 Technique for Colorectal Cancer Screening Summary Detection of genetic abnormalities associated with colorectal cancer in stool samples has been proposed

More information

Understanding Your Genetic Test Result. Positive for Two Copies of an MYH Mutation

Understanding Your Genetic Test Result. Positive for Two Copies of an MYH Mutation Understanding Your Genetic Test Result Positive for Two Copies of an MYH Mutation This workbook is designed to help you understand the results of your genetic test and is best reviewed with your healthcare

More information

Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN

Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Serrated Adenomas: What do they mean and what to do about them? Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN Colorectal Cancer Molecular Basis Pathway Frequency Genes MSI Precursor Speed

More information

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change

More information

Family history and the natural history of colorectal cancer: systematic review

Family history and the natural history of colorectal cancer: systematic review Family history and the natural history of colorectal cancer: systematic review Nora B. Henrikson, Group Health Research Institute Elizabeth M. Webber, Kaiser Permanente Center for Health Research Katrina

More information

Large Colorectal Adenomas An Approach to Pathologic Evaluation

Large Colorectal Adenomas An Approach to Pathologic Evaluation Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,

More information

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs

More information

CA Cancer J Clin 2006;56:

CA Cancer J Clin 2006;56: Guidelines for Colonoscopy Surveillance after Polypectomy: A Consensus Update by the US Multi- Society Task Force on Colorectal Cancer and the American Cancer Society *, Sidney J. Winawer, MD; Ann G. Zauber,

More information

Familial and Hereditary Colon Cancer

Familial and Hereditary Colon Cancer Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of

More information

Cost-effectiveness of adenoma surveillance - the Dutch guidelines -

Cost-effectiveness of adenoma surveillance - the Dutch guidelines - Cost-effectiveness of adenoma surveillance - the Dutch guidelines - WEO working group adenoma surveillance 20 May, 2016 Iris Lansdorp-Vogelaar, PhD On behalf of the SAP study-group Introduction Adenoma

More information

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female

More information

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You? A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is

More information

Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas.

Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas. Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas. Vanessa Cottet, Alexandre Pariente, Bernard Nalet, Jacques Lafon, Chantal Milan, Sylviane Olschwang,

More information

Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem

Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls Disclosures: None Jonathan P. Terdiman, M.D. Professor of Clinical Medicine University of California, San Francisco CRC: still a major public

More information

Colorectal Cancer Screening: A Clinical Update

Colorectal Cancer Screening: A Clinical Update 11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,

More information

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP) A Patient s Guide to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary

More information

50 세미만인구에서용종절제술로제거된대장선종의특성 : 대한장연구학회전향적다기관공동연구

50 세미만인구에서용종절제술로제거된대장선종의특성 : 대한장연구학회전향적다기관공동연구 50 세미만인구에서용종절제술로제거된대장선종의특성 : 대한장연구학회전향적다기관공동연구 The Characteristics of Colorectal Adenoma with Colonoscopic Polypectomy in Population under 50 Years Old: The KASID Prospective Multicenter Study Hyun Joo

More information

Adenomatous Polyposis Syndromes (FAP/AFAP and MAP)

Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) A Patient s Guide to risk assessment Adenomatous Polyposis Syndromes (FAP/AFAP and MAP) Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer

More information

Managing Moderate Penetrance

Managing Moderate Penetrance Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences

More information

Variation in Detection of Adenomas and Polyps by Colonoscopy and Change Over Time With a Performance Improvement Program

Variation in Detection of Adenomas and Polyps by Colonoscopy and Change Over Time With a Performance Improvement Program CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1335 1340 Variation in Detection of Adenomas and Polyps by Colonoscopy and Change Over Time With a Performance Improvement Program AASMA SHAUKAT,*, CRISTINA

More information

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy UvA-DARE (Digital Academic Repository) Population screening for colorectal cancer by colonoscopy de Wijkerslooth, T.R. Link to publication Citation for published version (APA): Wijkerslooth de Weerdesteyn,

More information

T he lifetime risk of developing colorectal cancer is 5%, with. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer CANCER

T he lifetime risk of developing colorectal cancer is 5%, with. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer CANCER 228 CANCER Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer G Lindgren, A Liljegren, E Jaramillo, C Rubio, A Lindblom... See end of article for authors affiliations... Correspondence

More information

What a history of cancer may mean for you and your family and the steps you can take to reduce the risk

What a history of cancer may mean for you and your family and the steps you can take to reduce the risk What a history of cancer may mean for you and your family and the steps you can take to reduce the risk www.myriadtests.com 1-800-469-7423 Family Ties and Colon Cancer In every family, certain traits are

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,

More information